FDA warning letters are up 156% since 2020 — 79% cite data integrity. Clinical trial data must be retained for 15+ years. Post-quantum signatures ensure every lab result, every chain of custody record, every temperature log is still legally valid in 2040.
Warning letters have reached record levels. ECDSA — the signature scheme protecting your trial data right now — won't survive the decade.
FDA warning letters are up 156% since 2020. Of those citing data integrity violations, 79% name it as the primary cause — not a secondary factor.
Clinical trial data must be retained 15+ years. ECDSA signatures — protecting most eTMF/EDC systems today — are projected to be breakable by quantum computers by 2035.
The average FDA 483 observation takes more than 3 years to resolve, with $500M+ in delayed approvals — all tracing back to preventable data integrity failures.
GENESIS attaches ML-DSA-65 + Ed25519 dual-signed receipts to the clinical data that must survive regulatory scrutiny in 2040.
Every test result — CBC, metabolic panel, biomarker assay — receives an ML-DSA-65 + Ed25519 signed receipt with subject ID, timestamp, lab operator, and instrument identifier baked in.
ML-DSA-65 + Ed25519Every sample handoff is cryptographically logged — from collection to analysis. Each transfer event generates a signed receipt linking collector, handler, recipient, time, and condition.
custody_chain · signed transferTemperature sensor readings from −80°C freezers, liquid nitrogen storage, and shipping containers generate signed receipts at configurable intervals. Excursions are flagged immutably.
IoT sensors · excursion logging21 CFR Part 11 mandates electronic audit trails for any regulated record. GENESIS builds ALCOA+-compliant audit trails automatically — every entry attributable, timestamped, original.
21 CFR Part 11 · ALCOA+Post-quantum ML-DSA-65 (FIPS 204) signatures remain valid through the quantum transition. Data signed in 2025 will be legally defensible in 2040 when your 15-year retention window closes.
FIPS 204 · 2040+ validOne-click export generates a signed ZIP containing the complete regulatory submission package — all receipts, audit trails, and verification keys — court-admissible out of the box.
signed ZIP · court-admissibleThe FDA's ALCOA+ framework defines what makes clinical data trustworthy. GENESIS satisfies each principle not through policy — but through cryptographic enforcement.
Every signed receipt embeds the cryptographic identity of the operator, instrument, and system that generated the data. Attribution cannot be forged or removed.
Receipts are structured JSON with a human-readable verification path. Any regulator with an open-source verifier can read and validate — no proprietary software required.
GENESIS signs records at capture time with a hardware-backed timestamp. Backdating is cryptographically impossible — the signature encodes the exact moment of creation.
The original signed receipt is immutable. Any subsequent amendment creates a new signed record referencing the original — the chain of custody is never broken.
Instrument readings are signed at the sensor level before any software processing. The signed receipt contains the raw measurement — no intermediate manipulation possible.
GENESIS enforces completeness requirements — every required field must be populated before a receipt can be signed. Incomplete records are rejected at the protocol layer.
All sites in a multi-center trial use the same cryptographic schema. Receipt format, signing key hierarchy, and verification process are identical across every CRO and laboratory.
ML-DSA-65 (FIPS 204) is NIST's post-quantum standard. Receipts signed today remain cryptographically verifiable after ECDSA is deprecated and quantum computers are mainstream.
Receipts are self-contained portable documents. No Hive infrastructure required for verification — any regulator or court can verify any receipt offline, at any time, anywhere.
Clinical trial data outlives the cryptography protecting it. Here is the timeline — and why waiting is not an option.
A drug trial submitted to the FDA in 2025 may be reviewed, litigated, or audited in 2042. The signatures on that data need to be valid for the entire window. ECDSA will not be.
The majority of eTMF and EDC systems use ECDSA-256 or RSA-2048 for signing clinical records. These algorithms are adequate today — but the clock is running.
Vulnerable if not upgradedNIST's post-quantum migration timeline calls for deprecation of ECDSA for applications requiring signatures to be valid beyond a 5–7 year horizon. Regulatory guidance follows.
NIST SP 800-131A Rev. 3Multiple intelligence agencies and national labs project cryptographically-relevant quantum computers (CRQCs) by the early 2030s. Shor's algorithm breaks ECDSA and RSA at scale.
Harvest now, decrypt later attacks activeA Phase III trial begun in 2025 reaches the end of its required retention period. Any data signed with ECDSA in 2025 may no longer be cryptographically verifiable — creating catastrophic regulatory exposure.
21 CFR Part 312.62 · ICH E6(R3)GENESIS applies NIST's finalized post-quantum digital signature standard at the moment of data capture. Every receipt is signed with ML-DSA-65 — the algorithm designed to survive the transition from classical to quantum computing.
FIPS 204 · ML-DSA-65 · Valid 2025–2045+GENESIS is a sidecar to your existing EDC, eTMF, and CTMS infrastructure — not a replacement. CRO partners can deploy in days, not quarters.
GENESIS is architected to run alongside the clinical operations platforms your CRO already uses. IQVIA, Parexel, and Covance partners can onboard via a pre-certified connector — no custom development required.
GENESIS runs as a sidecar process alongside your existing Electronic Data Capture and Trial Master File systems. Data events flow through a signing layer before storage — zero changes to existing workflows.
Zero workflow disruption Sidecar · not a replacementGENESIS integrates with the leading clinical data platforms through API-level connectors. No custom middleware, no proprietary hardware requirements.
When an FDA 483 observation arrives or a regulatory submission is due, GENESIS generates a signed ZIP containing every relevant receipt, audit trail, and verification key — ready for submission or litigation.
One-click signed ZIPPaper records, standalone eTMF/EDC systems, and GENESIS — side by side on the capabilities that regulators and courts actually evaluate.
| Capability | Paper + Manual | eTMF / EDC Only | GENESIS |
|---|---|---|---|
| Post-quantum signatures | N/A | ECDSA only | ML-DSA-65 (FIPS 204) |
| Offline verification | Manual review required | Vendor system required | Self-contained, no dependency |
| ALCOA+ compliant | Process-dependent | Partial — no crypto proof | Cryptographically enforced |
| FDA 483 defense | Weak — paper trail gaps | Partial — audit logs only | Signed receipts, court-admissible |
| 15-year integrity | Degradation risk | ECDSA breaks by 2035 | Valid through 2040+ |
| Court-admissible | Variable — jurisdiction risk | Depends on vendor | Signed ZIP, open verifier |
| 21 CFR Part 11 | Manual compliance | System-level only | Built-in, per-record |
| Cold chain signing | Paper logs | Not available | IoT sensor receipts |
GENESIS is currently accepting pilot partners — pharma companies with recent FDA 483 observations for data integrity, or CROs preparing Phase III submissions with 10+ year retention requirements.
Patent Pending · 21 CFR Part 11 · ALCOA+ · FIPS 204 · ML-DSA-65